Clinical trial
A Randomized, Open, Single-dose, 3 Period Partial Replicated Crossover-design Clinical Trial to Evaluate the Safety and Pharmacokinetic Characteristics After Administration of CKD-333 or Co-administration of CKD-330 and D085 in Healthy Volunteers Under Fasting Conditions
NCT04627207 is registered in ClinicalTrials.gov with Chong Kun Dang Pharmaceutical as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Randomized, Open, Single-dose, 3 Period Partial Replicated Crossover-design Clinical Trial to Evaluate the Safety and Pharmacokinetic Characteristics After Administration of CKD-333 or Co-administration of CKD-330 and D085 in Healthy Volunteers Under Fasting Conditions
- Lead sponsor
- Chong Kun Dang Pharmaceutical
- Phase
- Phase 1
- Overall status
- Unknown status
- Start date
- November 30, 2020
- Completion date
- April 30, 2021
- Enrollment
- 51 (estimated)
- Sites
- Not reported
Conditions
As the registry lists them; a condition with its own page is linked.